Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single and Multiple Dose Safety, Tolerability and Pharmacokinetics Study of MK-1167 in Healthy Japanese Adults
jRCT2031230399Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MK-1167 in Alzheimer's disease (AD) (4 arms), sponsored by Merck & Co. Primary endpoint: Safety and tolerability. Started Oct 2023; status: completed.
02
Drugs
MK-1167
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2031230399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230399.